{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T19:57:26Z","timestamp":1790539046390,"version":"4.1.0"},"reference-count":19,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.clinthera.2026.06.002","type":"journal-article","created":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T11:46:51Z","timestamp":1782733611000},"page":"1037-1044","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["A Phase I Study Assessing the Safety, Tolerability, and Pharmacokinetics of Yinfenidone: A Novel, Potent Drug for Idiopathic Pulmonary Fibrosis Treatment in Healthy Chinese Subjects"],"prefix":"10.1016","volume":"48","author":[{"given":"Meixian","family":"Ou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulei","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huijuan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingying","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanmei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2026.06.002_bib0001","article-title":"Dysregulated epithelial-mesenchymal crosstalk in idiopathic pulmonary fibrosis: a multi-omics validation","volume":"42","author":"Jones","year":"2023","journal-title":"Cell Rep"},{"key":"10.1016\/j.clinthera.2026.06.002_bib0002","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1164\/rccm.2009-040GL","article-title":"Evidence-based guidelines for diagnosis and management of idiopathic pulmonary fibrosis","volume":"183","author":"Raghu","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"issue":"Suppl 56","key":"10.1016\/j.clinthera.2026.06.002_bib0003","first-page":"P1463","article-title":"The evolving concept of the IPF epidemic in France","volume":"40","author":"Cottin","year":"2012","journal-title":"Eur Respir J"},{"key":"10.1016\/j.clinthera.2026.06.002_bib0004","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1183\/16000617.0077-2018","article-title":"The epidemiology of idiopathic pulmonary fibrosis and interstitial lung diseases at risk of a progressive-fibrosing phenotype","volume":"27","author":"Olson","year":"2018","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.clinthera.2026.06.002_bib0005","first-page":"15","article-title":"Global incidence and prevalence of idiopathic pulmonary fibrosis","volume":"16","author":"Hutchinson","year":"2015","journal-title":"Respir Res"},{"key":"10.1016\/j.clinthera.2026.06.002_bib0006","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1183\/09031936.00185114","article-title":"Global incidence and mortality of idiopathic pulmonary fibrosis: a systematic review","volume":"46","author":"Hutchinson","year":"2015","journal-title":"Eur Respir J"},{"key":"10.1016\/j.clinthera.2026.06.002_bib0007","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1056\/NEJMra1705751","article-title":"Idiopathic pulmonary fibrosis","volume":"378","author":"Lederer","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2026.06.002_bib0008","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1186\/s12916-015-0495-0","article-title":"Idiopathic pulmonary fibrosis in BRIC countries: the cases of Brazil, Russia, India, and China","volume":"13","author":"Richeldi","year":"2015","journal-title":"BMC Med"},{"key":"10.1016\/j.clinthera.2026.06.002_bib0009","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1016\/j.chest.2021.06.049","article-title":"Impact of antifibrotic therapy on mortality and acute exacerbation in idiopathic pulmonary fibrosis: a systematic review and meta-analysis","volume":"160","author":"Petnak","year":"2021","journal-title":"Chest"},{"key":"10.1016\/j.clinthera.2026.06.002_bib0010","first-page":"925","article-title":"Pirfenidone for idiopathic pulmonary fibrosis: analysis of outcomes in a real-world cohort","volume":"385","author":"Noble","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2026.06.002_bib0011","first-page":"e78","article-title":"Comparative efficacy and safety of antifibrotic therapies for idiopathic pulmonary fibrosis: a network meta-analysis","volume":"10","author":"Zhang","year":"2022","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.clinthera.2026.06.002_bib0012","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.838449","article-title":"BI 1015550 is a PDE4B inhibitor and a clinical drug candidate for the oral treatment of idiopathic pulmonary fibrosis","volume":"13","author":"Herrmann","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.clinthera.2026.06.002_bib0013","article-title":"Yinfenidone attenuates TGF-\u03b21-induced fibroblast activation through dual inhibition of SMAD and non-SMAD signaling","volume":"201","author":"Chen","year":"2024","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.clinthera.2026.06.002_bib0014","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects","volume":"310","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2026.06.002_bib0015","series-title":"Integrated addendum to ICH E6(R1): guideline for good clinical practice E6(R2)","year":"2016"},{"key":"10.1016\/j.clinthera.2026.06.002_bib0016","series-title":"Guideline for good clinical practice","year":"2020"},{"key":"10.1016\/j.clinthera.2026.06.002_bib0017","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S2213-2600(22)00260-0","article-title":"Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled, phase 2 study","volume":"11","author":"Solomon","year":"2023","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.clinthera.2026.06.002_bib0018","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-41550-2","article-title":"Targeting transforming growth factor beta using pirfenidone, a potential repurposing therapeutic strategy in colorectal cancer","volume":"13","author":"Jamialahmadi","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.clinthera.2026.06.002_bib0019","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1136\/thorax-2022-219795","article-title":"Pirfenidone in fibrotic hypersensitivity pneumonitis: a double-blind, randomised clinical trial of efficacy and safety","volume":"78","author":"Fern\u00e1ndez P\u00e9rez","year":"2023","journal-title":"Thorax"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014929182600189X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014929182600189X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T19:26:54Z","timestamp":1790537214000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S014929182600189X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":19,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S014929182600189X"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2026.06.002","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Phase I Study Assessing the Safety, Tolerability, and Pharmacokinetics of Yinfenidone: A Novel, Potent Drug for Idiopathic Pulmonary Fibrosis Treatment in Healthy Chinese Subjects","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2026.06.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}